PepMLM generates binders to challenging therapeutic targets across cancer and neurological disease using protein sequence and ...

Researchers demonstrate that an engineered antibody improves a class of drugs that has struggled to make good on its early promise.

Schrödinger has halted development of its cancer-fighting candidate SGR-2921 after two patients treated with the CDC7 inhibitor died in a Phase I trial.

Peptidoglycan hydrolases killed living bacteria, opening the door for further research into the interplay between archaea and bacteria.